GlassScriptPhysician profile
Shreya Nayak
NPI 1144614025
$3,287.76
in general payments reported to CMS, 2019-2025
28 companies · $362 in 2025
The $362 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $41.94 · 2021: $335 · 2022: $444 · 2023: $741 · 2024: $1,014 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $656.47 | 2019-2024 | Vumerity, Tysabri |
| Abbvie INC. | $467.24 | 2022-2025 | |
| Sk Life Science, INC. | $372.35 | 2021-2025 | Xcopri |
| Jazz Pharmaceuticals INC. | $233.23 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $227.09 | 2019-2023 | |
| Vanda Pharmaceuticals INC. | $169.37 | 2024-2025 | Ponvory |
| Tg Therapeutics, INC. | $162.84 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $126.86 | 2021-2024 | Austedo Xr |
| Genzyme Corporation | $107.70 | 2019 | |
| Amneal Pharmaceuticals LLC | $105.50 | 2020-2024 | Rytary |
| Amgen INC. | $96.93 | 2020-2025 | Uplizna |
| Lilly USA, LLC | $90.81 | 2020-2025 | Kisunla, Emgality |
| Alexion Pharmaceuticals, INC. | $66.19 | 2023-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $60.05 | 2022-2023 | Hyqvia |
| Celgene Corporation | $47.68 | 2022-2025 | Zeposia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $41.92 | 2022-2024 | Nourianz |
| Banner Life Sciences, LLC | $33.45 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $32.58 | 2021 | |
| Sumitomo Pharma America, INC. | $30.60 | 2023-2024 | Aptiom |
| Csl Behring | $24.07 | 2024 | Hizentra |
| Lundbeck LLC | $20.27 | 2024 | Vyepti |
| Argenx US, INC. | $18.65 | 2024 | Vyvgart Hytrulo |
| Greenwich Biosciences, INC. | $17.04 | 2021 | |
| Ucb, INC. | $16.45 | 2024 | Fintepla |
| Aprecia Pharmaceuticals, LLC | $16.27 | 2023 | Spritam |
| Upsher-Smith Laboratories LLC | $16.18 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.23 | 2022 | |
| Acadia Pharmaceuticals INC | $14.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shreya Nayak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.